Rankings
▼
Calendar
AMRX Q4 2022 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q4 2022 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$610M
+13.6% YoY
Gross Profit
$215M
35.3% margin
Operating Income
$36M
5.9% margin
Net Income
-$4M
-0.7% margin
EPS (Diluted)
$-0.04
QoQ Revenue Growth
+11.8%
Cash Flow
Operating Cash Flow
-$23M
Free Cash Flow
-$35M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$3.8B
Total Liabilities
$3.6B
Stockholders' Equity
$298M
Cash & Equivalents
$26M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$610M
$537M
+13.6%
Gross Profit
$215M
$166M
+29.4%
Operating Income
$36M
$11M
+222.4%
Net Income
-$4M
-$6M
+32.1%
Revenue Segments
Generics Segment
$399M
65%
Av K A R E Segment
$108M
18%
Amneal Specialty Pharma Segment
$103M
17%
← FY 2022
All Quarters
Q1 2023 →